Multiple sclerosis (MS) is associated with a variety of symptoms and functional deficits that
result in a range of progressive impairments and handicap. Symptoms that contribute to loss …

Disease-modifying drugs have mostly failed as treatments for progressive multiple sclerosis.
Management of the disease therefore solely aims to minimise symptoms and, if possible …

Management of symptoms in multiple sclerosis (MS) has received little attention compared
with disease-modifying treatments. However, the effect of these symptoms on quality of life …

Rehabilitation still the only way to improve function in multiple sclerosis. КОРЗИНА ПОИСК
НАВИГАТОР ЖУРНАЛЫ КНИГИ ПАТЕНТЫ ПОИСК АВТОРЫ ОРГАНИЗАЦИИ …

Overall, there is an encouraging trend both in questioning our current practice and in
designing more scientifically sound trials incorporating new and more appropriate outcome …

Multiple sclerosis is a complex, heterogeneous disease associated with long-term disability.
Despite the availability of advanced disease-modifying and symptomatic therapies that may …

Summary About 10–15% of patients with multiple sclerosis (MS) present with gradually
increasing neurological disability, a disorder known as primary-progressive multiple …

Many of the available disability outcome measures used in clinical trials of multiple sclerosis
are insensitive to change over time, inadequately validated, or insensitive to patient …

The secondary progressive phase of multiple sclerosis (MS), which is characterised by a
steady accrual of fixed disability after an initial relapsing remitting course, is not clearly …

Background: Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative
disease. Over time, symptoms accumulate leading to increased disability of patients …